Panax Ginseng — Medicine Atlas

Atlas Three · Medicine · Traditional · Adaptogen / Tonic

Panax Ginseng (Korean Red Ginseng)

Botanical name: Panax ginseng C.A. Meyer (Araliaceae) | Route: Oral | Category: Adaptogen / Traditional tonic

Korean Red Ginseng root; ginsenosides (Rb1, Rg1, Re) modulate the HPA stress axis, stimulate eNOS phosphorylation (Ser1177) via Akt → NO-mediated vasodilation, upregulate GLUT4 translocation via AMPK, and boost NK-cell cytotoxicity. Moderate evidence for erectile dysfunction and fatigue; low-moderate evidence for glycaemic improvement in type 2 diabetes. Potentiates warfarin via possible CYP2C9 induction — monitor INR if co-prescribed.

Korean Red Ginseng Asian ginseng Chinese ginseng ren shen 인삼 ginsenoside KRG white ginseng panax ginseng

Overview

Panax ginseng C.A. Meyer (family Araliaceae) is the premier adaptogenic plant of East Asian medicine, cultivated for over 2,000 years in Korea, China, and Manchuria. The name Panax derives from the Greek panacea ("cure-all"), reflecting its revered status in traditional therapeutics. The pharmacologically active part is the fleshy root, which requires 4–6 years of growth to accumulate sufficient active constituents. Processing determines the product form: White ginseng is air-dried after peeling at 4–5 years, producing a milder preparation; Korean Red Ginseng (KRG) is prepared from the unpeeled root steamed at 100°C then dried, with the Maillard reaction producing additional ginsenosides (Rg3, Rh1, compound K) unique to KRG and responsible for its stronger pharmacological profile.

The pharmacologically active constituents are ginsenosides (also called panaxosides) — dammarane-type triterpenoid saponins classified by their aglycone into two main series. The Protopanaxadiol (PPD) series (Rb1, Rb2, Rc, Rd) is generally sedating and inhibitory, with neuroprotective and antiproliferative properties. The Protopanaxatriol (PPT) series (Rg1, Re, Rf) is generally stimulating and excitatory, activating the CNS and stimulating eNOS. The dual and opposing activity of ginsenosides at many receptors — depending on concentration, metabolic conversion, and structural class — complicates pharmacological characterisation.

Gut microbiota metabolise ginsenosides to more bioavailable aglycones (protopanaxadiol, compound K), which may account for substantial inter-individual variation in clinical response. Panax ginseng is pharmacologically distinct from Siberian ginseng (Eleutherococcus senticosus, which contains eleutherosides, not ginsenosides) and American ginseng (Panax quinquefolius, which lacks the PPT ginsenoside series).

Mechanism of Action

HPA Axis Modulation and Adaptogen Activity

  Stress stimulus
        │
        ▼
  CRH (hypothalamus)
        │
        ▼
  ACTH (pituitary)  ←── Rg1 / Rb1 reduce CRH / ACTH release
        │
        ▼
  Cortisol (adrenal cortex)
        │
        ▼
  Hippocampus (HPA negative feedback)
        │
        ├── Rg1 → estrogen receptor-β → PKA/CREB → neuroprotection
        └── Rb1 → BDNF ↑ via cAMP/CREB → protects hippocampal neurons
                             from glucocorticoid-mediated apoptosis

Glucocorticoid / estrogen receptor modulation: Ginsenosides Rg1 and Rb1 bind GR with low affinity; Rg1 also activates estrogen receptor-α/β — both receptors modulate HPA axis feedback sensitivity and downstream neuroprotection
CRH/ACTH suppression: Ginseng extracts reduce corticotropin-releasing hormone (CRH) and ACTH release in animal stress models, blunting the cortisol surge and attenuating the overall stress response
eNOS activation (NO pathway): Ginsenosides (Rg1, Re, KRG compounds) phosphorylate eNOS at Ser1177 via Akt → increased NO production in vascular endothelium and corpus cavernosum → smooth muscle relaxation → vasodilation and improved erectile function
AMPK / GLUT4 (metabolic): Rb1 activates AMPK → GLUT4 translocation to plasma membrane in skeletal muscle → insulin-independent glucose uptake; Rg1 enhances IRS-1 phosphorylation amplifying downstream insulin signalling
Immunomodulation: Rg1 and Re activate TLR4-mediated signalling in macrophages, upregulating NK-cell cytotoxicity and dendritic cell maturation; Rb1 provides counter-regulation via IL-10 and TGF-β to prevent excessive inflammation

Pleiotropic Mechanisms

Neuroprotection (Rb1 / Rg1 / Rg3)

Rb1 upregulates BDNF via cAMP/CREB in hippocampus; Rg1 inhibits β-amyloid aggregation and reduces tau phosphorylation via CDK5 inhibition; Rg3 (enriched in KRG) is anti-apoptotic and neuroprotective

PPAR-γ Partial Agonism

Certain ginsenosides act as partial PPAR-γ agonists, promoting adipocyte differentiation and improving insulin sensitivity in adipose tissue — weaker than thiazolidinediones but mechanistically parallel

Antiplatelet / Calcium Channel (Rg3)

Rg3 blocks L-type Ca²⁺ channels inhibiting vasoconstriction; has antiplatelet properties reducing thrombotic risk; modest systolic BP reductions consistently reported in clinical RCTs

Vaccine Adjuvant Effect

KRG co-administration with influenza vaccine increases haemagglutination inhibition titres in elderly RCTs (Predy et al. 2005); enhanced CD4+/CD8+ T-cell ratios and Th1/Th2 balance documented

Clinical Use & Dosing

Indication	Evidence Level	Standard Dose	Duration Studied
Erectile dysfunction	Moderate	KRG 900 mg three times daily (2,700 mg/day)	8–12 weeks
Type 2 diabetes / glycaemia	Low-Moderate	Panax ginseng 200 mg/day (standardised extract)	8–24 weeks
Fatigue / physical endurance	Low	400–3,000 mg/day (variable formulations)	4–12 weeks
Immune function (cold/influenza)	Low-Moderate	KRG 1,800 mg/day	12 weeks
Cognitive function	Low	400 mg/day standardised extract	8–24 weeks
Menopausal symptoms	Low	KRG 3 g/day	12 weeks

Doses vary substantially across trials due to differing extract standardisation. KRG preparations typically target ≥20 mg total ginsenosides per 1.5 g root equivalent. The Shishtar et al. (2014) meta-analysis identified 200 mg standardised extract as the best-studied preparation for glycaemic control.

Key Studies

Study	Design / n	Key Result
Kim et al. (2009) Asian J Androl	RCT, crossover, n=119; KRG 900 mg 3× daily, 8 weeks vs placebo	Significant IIEF score improvement vs placebo; rigidity subscale p<0.05; 60% of men reported improved erections vs 30% placebo; eNOS/NO mechanism confirmed in corpus cavernosum
Shishtar et al. (2014) PLoS One	Meta-analysis, 16 RCTs, n=770; Panax species (predominantly P. ginseng and P. quinquefolius)	Fasting blood glucose −0.31 mmol/L (95% CI: −0.61 to −0.01); HOMA-IR non-significant trend; I² ~60–70%; statistically significant but clinically modest effect
Predy et al. (2005)	Double-blind RCT, n=323; CVT-E002 (North American ginseng) 400 mg/day, 4 months during influenza season	≥2 colds: 10% vs 23% (p=0.004); cold duration 10.8 vs 16.5 days; note: P. quinquefolius, not KRG — results may not translate directly
Jang et al. (2008) BJU Int systematic review	Systematic review, 6 RCTs, n=45–135 each; erectile dysfunction	All 6 RCTs showed benefit for erectile dysfunction; consistent direction of effect; all small and at risk of bias; eNOS mechanism biologically well-supported

Core Insight: Panax ginseng's most robust clinical evidence is for erectile dysfunction — where its eNOS-mediated NO mechanism directly parallels (but operates upstream of) PDE5 inhibitors — and for modest glycaemic improvement, where AMPK-mediated GLUT4 translocation explains the insulin-sensitising effect. Evidence for cognitive enhancement and longevity claims remains insufficient for clinical recommendation. Most positive trials are small, short-duration, and conducted in Asian populations.

Safety & Drug Interactions

Warfarin interaction (clinically significant): Ginseng reduces INR — case reports and a small crossover RCT (Janetzky & Morreale, 1997) demonstrate lowered warfarin anticoagulant effect; mechanism possibly CYP2C9 induction; monitor INR closely if co-prescribed; may require warfarin dose increase
Insulin / sulfonylureas (additive hypoglycaemia): Additive glucose-lowering via AMPK-mediated GLUT4 upregulation; fasting glucose monitoring recommended when combining with antidiabetic pharmacotherapy
MAOIs (avoid): Case reports of headache, tremor, and mania with concurrent ginseng; potential serotonin/catecholamine augmentation — combination should be avoided
Immunosuppressants (cyclosporine, tacrolimus — caution): Ginsenoside immunostimulation may counteract graft rejection prophylaxis; interaction poorly characterised but biologically plausible — avoid in transplant recipients without specialist guidance
Digoxin (laboratory interaction only): Ginseng interferes with some digoxin immunoassays, producing falsely elevated readings — a laboratory artefact, not pharmacokinetic; confirm with LC-MS/MS assay if suspected toxicity
Common adverse effects: Insomnia, nervousness, headache (especially high doses or stimulant combinations); GI upset; breast tenderness and mastalgia at high doses (estrogenic ginsenoside activity)
Contraindications: Hormone-sensitive conditions (breast, uterine, ovarian cancer; endometriosis) due to estrogenic ginsenoside activity; bipolar disorder (mania risk); concurrent MAOI use; pregnancy (ginsenoside Rb1 teratogenic in animal models — avoid)

Connections

Modulates Nervous System Modulates Immune System Modulates Cardiovascular System

References

Kim TH, Jeon SH, Hahn EJ, et al. Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction. Asian J Androl. 2009;11(3):356-61. doi:10.1038/aja.2008.32
Shishtar E, Sievenpiper JL, Djedovic V, et al. The effect of ginseng (the genus Panax) on glycemic control. PLoS One. 2014;9(9):e107391. doi:10.1371/journal.pone.0107391
Predy GN, Goel V, Lovlin R, et al. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections. CMAJ. 2005;173(9):1043-8.
Jang DJ, Lee MS, Shin BC, et al. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66(4):444-50. doi:10.1111/j.1365-2125.2008.03236.x
Evans WC. Trease and Evans' Pharmacognosy. 16th ed. Saunders; 2009.